Versican Plus Pi/L4R
canine parainfluenza virus, leptospira and rabies virus
Table of contents
Overview
This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Versican Plus Pi/L4R
|
Agency product number |
EMEA/V/C/003682
|
Active substance |
canine parainfluenza virus, leptospira and rabies virus.
|
International non-proprietary name (INN) or common name |
canine parainfluenza virus, leptospira and rabies virus
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07AJ
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium S.A.
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
30/07/2014
|
Contact address |
Rue Laid Burniat, 1 |
Product information
17/04/2019 Versican Plus Pi/L4R - EMEA/V/C/003682 - IB/0014
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for canidae
-
Live and inactivated viral and bacterial vaccines
Therapeutic indication
Active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by Leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.